Moreover, as a rate-limiting enzyme, GCLC catalyzing activity is subject to feedback inhibition by GSH [11], and abnormal expression is closely related to tumor progression and drug resistance in different histological types of human cancers [12, 13]. This evidence concerns the gene GCLC and cancer.